NeoGenomics Laboratories  

The NeoTYPE Lymphoid Disorders Profile is intended to aid in the diagnosis and sub-classification of lymphoid neoplasms, identify potential therapies based on the patient’s unique molecular drivers, and provide information for predicting prognosis of the malignancy in question.  It is also useful in the differential diagnosis of cell of origin: germinal center B-cell like vs. activated B-cell like lymphoma, as in diffuse large B-cell lymphoma.  It can also be used to build genomic databases for academic or clinical research purposes.

The NeoTYPE ALL Profile is intended as an aid in diagnostic subtyping, risk assessment, and therapy selection of acute lymphoblastic leukemia (ALL) with a focus on Ph+ and Ph-like B-ALL subtypes. It is appropriate for both adult and pediatric ALL patients.  Sequencing DNA and RNA via NGS, NeoTYPE ALL Profile detects SNVs/InDels in 21 genes, copy number variations in 3 tumor-suppressor genes (CDKN2A, IKZF1, and TP53), fusions in 30 genes, and gene overexpression in 2 genes (CRLF2 and EPOR).  FISH components are also included to detect IGH::CRLF2 and IGH::EPOR fusions.

The NeoTYPE Discovery Profile for Hematologic Cancers is intended for predictive and prognostic purposes in the management of hematologic disease, but may also aid in the diagnosis/subtype in some cases in conjunction with other clinical and laboratory test results.  The profile covers 302 genes implicated in the pathogenesis of hematologic malignancies, such as AML, CLL, MPN, MDS, and lymphomas.  It is useful for patients with complex or conflicting clinical and/or diagnostic results where insight into the biology may inform diagnosis, aid in classification, and/or identify potential therapeutic options.  It can also be used to build genomic databases for academic or clinical research purposes.

COMPASS Select is optimized for pathologists who perform morphologic evaluation locally. Existing morphology results are seamlessly integrated into the assessment with only further medically necessary tests performed to arrive at a conclusive diagnosis without excess testing.  Each case is guided by a board-certified hematopathologist evaluating all clinical and laboratory information provided to deliver a final and actionable diagnosis with a summary assessment for every unique patient.  Test includes COMPASS® consultation report, clinical pathology evaluation, flow cytometry, cytogenetics and/or fluorescent in situ hybridization (FISH), and molecular tests as medically necessary.

The PD-L1 SP263 FDA (TECENTRIQ®) for NSCLC is a qualitative IHC assay utilizing the FDA-approved VENTANA PD-L1 (SP263) companion diagnostic (CDx) test. This CDx test is indicated as an aid in identifying Stage II to IIIA NSCLC patients eligible for treatment with TECENTRIQ® (atezolizumab) whose tumor expresses PD-L1 on ≥ 1% of tumor cells (TC) of any intensity. The use of an FDA-approved CDx test for PD-L1 provides clinicians an effective tool for navigating targeted immunotherapy treatment options for patients.